Sarnia Researchers Join Alzheimer’s Drug Trial Nationwide

A new clinical trial for reternetug, a monoclonal-antibody drug developed by Eli Lilly, is underway to prevent amyloid and tau protein buildup in the brains of individuals aged 65 to 80 with a family history of Alzheimer's, but without any diagnosed symptoms. This trial follows the FDA's approval of drugs like donanemab and the recent development of new diagnostic criteria that allow for early detection of Alzheimer's through brain scans and blood tests. While these advancements hold promise, questions remain about the implications of early diagnosis when effective treatments are still limited. Additionally, recent findings indicate that two new drugs, Leqembi and Kisunla, can slow cognitive decline in Alzheimer's patients, although individual responses vary widely. Investigative journalist Charles Piller has raised concerns about the integrity of Alzheimer's research, particularly regarding the amyloid hypothesis, suggesting a need for more scrutiny in the field. Overall, while research and treatment options are evolving, the path forward remains complex and uncertain.